A period of PN is almost always required after a major intestinal resection. Small bowel that remains after the resection generally demonstrates enhanced absorptive function through numerous mechanisms collectively described as "adaptation." 7, 8 Adaptation may be sufficient to permit restoration of nutritional autonomy even in cases where the magnitude of intestine loss is extensive. In the absence of complete adaptation, patients remain committed to varying amounts of supplemental PN indefinitely.
Several factors predict long-term PN, including a remnant jejunoileal length <50 to 100 cm in older children and adults and <20
to 40 cm in small children; failed adaptation with greater lengths of small bowel results when enterocolonic continuity and/or the ileocecal valve and most of the colon are not preserved. 7, 9, 10 When patients with IF (ie, incomplete adaptation) experience complications on PN that threaten survival, intestine transplant is indicated. 3 These complications include recurrent life-threatening central line-associated sepsis, extensive central vein thrombosis that precludes confident preservation of PN catheter access, progressive IFALD, and repeated episodes of severe dehydration and associated electrolyte disorders that are refractory to standard management.
11,12
3 | I FA LD
| Definition and pathophysiology
Although PN therapy has revolutionized the treatment of IF, it is associated with significant complications. Liver and biliary tract disease represents one of the most important and lethal PN complications. 13 While there is no consistent classification of IFALD, elevation of ≥ 1 liver chemistry tests (alkaline phosphatase, γ-glutamyl transferase, aspartate transaminase, alanine transaminase) to >1.5
times the upper limit of the reference range for at least 2 weeks in the absence of another cause is a generally accepted definition. 14, 15 This definition encompasses the earliest and mildest liver dysfunction in IFALD.
IFALD is more common in children than in adults, with incidences of mild IFALD equaling 50% and 30% after 4 to 12 weeks of treatment, respectively. [16] [17] [18] [19] The lesion associated with IFALD differs based on age, with children demonstrating cholestasis and inflammation, while steatosis is more prevalent in adults.
Progression of IFALD to chronic and advanced disease, including fibrosis, cirrhosis, portal hypertension, and ultimately hepatocellular failure, occurs with an incidence estimated between 25% and 40% and is thought to be more common in young children than in adults. [16] [17] [18] [19] The pathophysiology of IFALD is poorly understood but appears to be multifactorial. Importantly, the increased incidence and severity of IFALD in children suggest that the immaturity of the liver may play a role in the progression of the disease. 17, 18, 20 In addition to the original ischemic or necrotic gut event, recurring catheter infections may produce a sustained or intermittent systemic inflammatory response that is associated with influx of cytokines and bacterial toxins to the liver, inducing inflammation and collagen synthesis. Further liver injury follows diminished bile acid clearance, creating a vicious pathologic cycle. Additional risk factors for IFALD include older age (>40-50 years), extreme SBS with <25 cm of small intestine in pediatric patients or <100 cm in adults, 16 lack of an ileocecal valve, 21 intestinal stasis and bacterial overgrowth, 22 and various apparently hepatotoxic components of PN.
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| Treatment
The only proven treatment for IFALD is PN reduction with increased enteral feeding that is made possible by adaptation of the remnant bowel or by intestine replacement with a transplant. 16, 23, 24 No specific amount or fraction of enteral nutrition (EN) has been shown reliably to interdict progressive IFALD and may vary be- 
| Intravenous lipid emulsion advancements
One of the most important recent advancements in the management of IFALD is the development of liver-sparing lipid emulsions.
Specifically, increasing evidence supports the substitution of soy oil-based intravenous lipid emulsion high in ω6 polyunsaturated fatty acids with preparations derived from fish oil rich in ω3 fatty acids. 19, 32, 33 The underlying mechanisms of ω6 fatty acid-induced liver injury is related to oxidative stress and inflammatory mediators and is an area of intense investigation. 32, 33 Reversal of cholestasis using fish oil lipid emulsions rich in 
52-54
The IRP has also been shown to improve the outcomes of transplant candidates. In 2015, Avitzur et al. reported a decrease in pretransplant mortality in the era after IRP initiation. 55 Interestingly, the cause of death in these patients changed from IFALD to other conditions typically related to prematurity. Furthermore, patients with ESLD as a result of IFALD and who were listed to receive a transplant had significantly improved conjugated bilirubin, albumin, and platelet counts.
| VISCER AL TR AN S PL ANT FOR IFALD

| Graft selection
The term "intestinal transplant" includes not only isolated intestinal transplant but also combined liver-intestinal and multivisceral transplants ( Table 1 Some evidence of hepatic synthetic dysfunction is typical, with hypoalbuminemia and coagulopathy that are variably mild to severe even in the setting of fully established cirrhosis. In adults, progression of IFALD to advanced disease is often unapparent until the onset of jaundice, after which the mortality is 100% within 10 to 18 months without transplant. 25 Similarly, reappearance of jaundice after the newborn period is usually an ominous sign in children, often first precipitated by a septic event. 17 Decompensation is heralded mainly by stoma bleeding and portosystemic encephalopathy and, perhaps, increased frequency and severity of septic events. As in adults, jaundiced children may appear deceptively well until decompensation, after which survival is short, only 8 weeks in 1 report. and demographic characteristics were not predictive. 56 Specifically, the predicted probability of eventual liver failure was 36% to 38%
| Liver-inclusion intestine transplant
at ages 3 to 6 months when the total bilirubin level was 6 mg/dl, platelet count was 220 000/μL, and albumin level was 3.5 g/dL. This probability increased to 83% to 84% when the total bilirubin level was 11.7 mg/dL, platelet count was 168 000/μL, and albumin level was 3 g/dL.
Based on these data, general guidelines can be formulated. First, the combination of hyperbilirubinemia and portal hypertension expressed as hepatosplenomegaly and thrombocytopenia is predictive of irreversible liver failure. Given the substantial wait time for a suitable liver and intestine allograft, a steady or climbing total bilirubin level of 100 μmol/L (6 mg/dL) with marked hepatosplenomegaly or thrombocytopenia ≤150 000/μL indicates combined liver-intestine listing. Second, progression of IFALD to histologic cirrhosis is not required to list for liver transplant, because death from liver failure is equally probable with only extensive bridging fibrosis. 57 Notably, these criteria may be changing with improved medical management of IFALD; this is discussed later.
| Isolated intestine transplant
Early IFALD may resolve after either successful adaptation of the remnant small intestine or after isolated intestine trans- 
| Isolated liver transplant
Intestinal adaptation and nutritional independence in patients with SBS may take several years. Because adaptation is impeded by IFALD, 60,61 liver failure develops in some patients for whom eventual complete adaptation can be predicted on the basis of favorable intestinal anatomy. When advanced IFALD appears to be the sole obstacle to successful adaptation, isolated liver transplant may be more appropriate than combined liver-intestine transplant. Furthermore, isolated liver transplant has significantly lower waitlist mortality, particularly in the pediatric population, because of greater donor organ availability due to standardized reduction of deceased donor grafts and the availability of living donor liver transplant. 1, 57 Another advantage of isolated liver transplant is less immunosuppression requirement in comparison with combined liver-intestine transplant.
Predicting which patients are able to achieve enteral independence after isolated liver transplant and thereby are appropriate candidates for the operation can be difficult. The critical parameter of intestine function in these patients is the maximum enteral tolerance despite the presence of IFALD. The Nebraska group reported the largest experience with isolated liver transplant in children with SBS and IFALD. 62, 63 In this study, minimal enteral tolerance of 50% of total calories, small intestine length >25 cm from ligament of Treitz, and patient age <2 years were predictive of successful enteral independence after transplant. These criteria can be used as guidelines for isolated liver transplant in patients with IFALD.
| E VOLVING IND I C ATI ON S FOR INTE S TINE TR AN S PL ANT
Successful liver-sparing PN practices combined with the adoption of comprehensive, multidisciplinary approaches to IF management may be decreasing the incidence of ESLD in IF 31, 64, 65 In recent analysis of the UNOS database by Khan et al., there was a dramatic decrease in the number of patients listed for combined liver-intestine transplant, particularly in the pediatric population, suggesting reduced referrals for liver failure. These data represent a cumulative effect of multiple improvements in the management of IFALD and is a paradigm shift in the field of IF. 66 The improvement in IFALD outcomes and decreasing requirement for liver-inclusive transplant have prompted discussion for revised intestinal transplant listing criteria. In a single-center study evaluating pediatric patients treated in a modern era, historic listing criteria were no longer predictive of mortality or need for transplant. 67 In this study, cholestasis was predictive only if a patient failed 6 weeks of liver-sparing lipid strategies. If validated in a larger study, these data will likely continue to contribute to the changing role of transplant for the patient with IF.
| INTE S TINE TR AN S PL ANT OUTCOME S
Short-term outcomes after intestinal transplant are now excellent because of progressive surgical advances, better control of acute cellular rejection, and a decrease in lethal infections. 68 Short-term survival after isolated intestine transplant is superior to multiorgan transplant, because it is a lesser procedure that is performed in patients who are not in liver failure. 59 
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